Journal Der Deutschen Dermatologischen Gesellschaft最新文献

{"title":"Kurzvorträge","authors":"","doi":"10.1111/ddg.70551","DOIUrl":"https://doi.org/10.1111/ddg.70551","url":null,"abstract":"","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":"24 S5","pages":"S45-S122"},"PeriodicalIF":5.0,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148962549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two Blastic Plasmacytoid Dendritic Cell Neoplasms treated with the CD123-targeted agent Tagraxofusp presenting divergent outcomes.","authors":"Sven C Engler, Elisabeth M Walde, Edgar Jost, Amir S Yazdi, David Kluwig","doi":"10.1111/ddg.70608","DOIUrl":"https://doi.org/10.1111/ddg.70608","url":null,"abstract":"","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148963417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Freie Vorträge","authors":"","doi":"10.1111/ddg.70550","DOIUrl":"https://doi.org/10.1111/ddg.70550","url":null,"abstract":"","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":"24 S5","pages":"S4-S44"},"PeriodicalIF":5.0,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148962548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhalt","authors":"","doi":"10.1111/ddg.70552","DOIUrl":"https://doi.org/10.1111/ddg.70552","url":null,"abstract":"","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":"24 S5","pages":"S1-S3"},"PeriodicalIF":5.0,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ddg.70552","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148962597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ePoster","authors":"","doi":"10.1111/ddg.70549","DOIUrl":"https://doi.org/10.1111/ddg.70549","url":null,"abstract":"","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":"24 S5","pages":"S123-S158"},"PeriodicalIF":5.0,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148962550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A large multilobulated cutaneous nodule in infancy.","authors":"Hannah Wahida, Andy Yan, Stephan Forchhammer","doi":"10.1111/ddg.70614x","DOIUrl":"https://doi.org/10.1111/ddg.70614x","url":null,"abstract":"","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148963391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of the Essen Melanoma Quality of Life Inventory (EMQoLI)","authors":"Venja Musche,&nbsp;Theresa Schadendorf,&nbsp;Adam Schweda,&nbsp;Georg Lodde,&nbsp;Jessica Neumann,&nbsp;Lisa Zimmer,&nbsp;Svea Hüning,&nbsp;Dirk Schadendorf,&nbsp;Eva-Maria Skoda,&nbsp;Elisabeth Livingstone,&nbsp;Martin Teufel","doi":"10.1111/ddg.15998","DOIUrl":"10.1111/ddg.15998","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>New treatments for melanoma, such as targeted therapy and immunotherapy, present unique adverse events compared to traditional treatments like surgery and chemotherapy. Existing health-related quality of life (HRQoL) measures often fail to address these new treatment effects and focus primarily on chemotherapy and surgery. This study aimed to develop and validate a new HRQoL instrument for melanoma patients across all tumor stages, encompassing a broader range of adverse events and melanoma-specific aspects.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and Methods</h3>\u0000 \u0000 <p>The Essen Melanoma Quality of Life Inventory (EMQoLI) was tested with 387 German-speaking malignant melanoma patients across all tumor stages.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Exploratory factor analysis revealed a three-factor structure. Eight items were removed due to low or cross-loading, leaving a final version of 25 items with satisfactory reliability and internal consistency. Correlation analyses indicated good convergent and discriminant validity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The EMQoLI is a 25-item German self-report tool based on a 5-point Likert scale, designed to assess HRQoL in melanoma patients across all tumor stages. It offers healthcare professionals an efficient tool to identify patients needing psychosocial support and can serve as a standardized measurement instrument in clinical settings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":"24 9","pages":"1241-1249"},"PeriodicalIF":5.0,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ddg.15998","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147722779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer survivorship in malignant melanoma","authors":"Markus Reitmajer,&nbsp;Susanne Dugas-Breit,&nbsp;Chiara L. Blomen,&nbsp;Elisabeth Livingstone,&nbsp;Max Schlaak,&nbsp;Markus V. Heppt,&nbsp;Michael M. Sachse,&nbsp;Madlen Hörold,&nbsp;Friedegund Meier,&nbsp;Sebastian Haferkamp,&nbsp;Christian Apfelbacher,&nbsp;Georgia Schilling,&nbsp;Andrea von den Berg,&nbsp;Frank Meiss,&nbsp;Lisa Zimmer,&nbsp;Andrea Forschner","doi":"10.1111/ddg.70486x","DOIUrl":"https://doi.org/10.1111/ddg.70486x","url":null,"abstract":"<p>Robust long-term survival data have transformed the prognosis of metastatic melanoma. For combination therapy with immune checkpoint inhibitors (ICIs), 10-year melanoma-specific survival rates now exceed 50 %, and durable disease control is achievable in a substantial proportion of patients, including those with brain metastases.</p><p>With increasing long-term survival, chronic and late-onset treatment-related toxicities are becoming increasingly relevant. In particular, chronic immune-related adverse events (irAEs) may persist after discontinuation of ICI therapy or emerge with delayed onset. These toxicities can significantly impair long-term quality of life and often require ongoing management; endocrine toxicities, for example, may necessitate lifelong hormone replacement therapy.</p><p>In addition to physical sequelae, survivors frequently experience psychosocial and financial burdens, difficulties returning to work, and concerns related to fertility and family planning. These multidimensional challenges highlight the growing importance of survivorship care in patients treated with ICIs.</p><p>Systematic assessment of physical and psychosocial burden as well as health-related quality of life, especially through patient-reported outcomes, can support clinical decision-making and individualized follow-up strategies. Integrating these assessments into structured, multidisciplinary survivorship care models is essential to address the complex long-term needs of melanoma survivors and to optimize outcomes beyond disease control.</p>","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":"24 9","pages":"e1291-e1308"},"PeriodicalIF":5.0,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ddg.70486x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148903985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab for the treatment of eczema molluscatum: A pediatric case report and systematic literature review","authors":"Patrick E. Obermeier,&nbsp;Uda Puzich,&nbsp;Annika Brinkmann,&nbsp;Livia Schrick,&nbsp;Alexandra Mühlendyck","doi":"10.1111/ddg.70176","DOIUrl":"10.1111/ddg.70176","url":null,"abstract":"<div>\u0000 \u0000 <p>Atopic dermatitis (AD) may be complicated by disseminated molluscum contagiosum virus (MOCV) infection, known as eczema molluscatum (EM), particularly in children. Topical treatments are not always effective, and although modern systemic immunomodulatory therapies for AD, including use in early childhood, are available, their impact on co-occurring MCV infection is not well documented. We present a 4-year-old child with severe EM that was refractory to conventional topical therapy. She was treated with dupilumab (300 mg subcutaneously every four weeks), which led to a rapid resolution of symptoms and clinical clearance of MOCV-1 infection without adverse events. To contextualize our findings, we performed a systematic literature review, including PubMed, ScienceDirect, Scopus, and Google Scholar, to identify published case descriptions of dupilumab use with co-occurring MOCV infection (PROSPERO ID CRD420251106639). We identified a total of six publications reporting on nine adult patients (mean age: 40 years, range: 21–58 years, 8/9 male). In five of these patients, EM temporarily flared up before resolution. The present report is the first of a child. Our findings, along with existing reports, suggest that dupilumab may be a safe and effective treatment option for AD patients with MOCV infection. Prospective evaluation using standardized outcome measures is warranted.</p>\u0000 </div>","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":"24 9","pages":"e1214-e1219"},"PeriodicalIF":5.0,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147838058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Einstellungen dermatologischer Patienten gegenüber digitalen Gesundheitsinterventionen: Eine Querschnittsbefragung und Clusteranalyse","authors":"Patrick Reinders,&nbsp;Matthias Augustin,&nbsp;Marina Otten","doi":"10.1111/ddg.70010x","DOIUrl":"https://doi.org/10.1111/ddg.70010x","url":null,"abstract":"&lt;p&gt;Die Dermatologie ist durch das weit verbreitete Auftreten von Hauterkrankungen gekennzeichnet, darunter häufige chronische Hautkrankheiten wie Akne, Psoriasis, atopische Dermatitis und Hautkrebs.&lt;span&gt;&lt;sup&gt;1, 2&lt;/sup&gt;&lt;/span&gt; In Deutschland sind jährlich etwa 27 % der Erwachsenen von mindestens einer dermatologischen Erkrankung betroffen. Dies führt zu einer vergleichsweise hohen Fallzahl und damit zu langen Wartezeiten auf einen Termin bei einem niedergelassenen Facharzt.&lt;span&gt;&lt;sup&gt;3, 4&lt;/sup&gt;&lt;/span&gt; Darüber hinaus wird davon ausgegangen, dass sich die Kapazitätsengpässe durch den demografischen Wandel noch weiter verschärfen werden.&lt;span&gt;&lt;sup&gt;4-7&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Als Ansatz für eine nachhaltige Gesundheitsversorgung zielen digitale Gesundheitsinterventionen (digital health interventions; DHI) darauf ab, die Versorgungsqualität zu verbessern, die Effizienz zu steigern und Patienten zu stärken.&lt;span&gt;&lt;sup&gt;8, 9&lt;/sup&gt;&lt;/span&gt; In dieser Studie beziehen sich DHI auf Gesundheitsdienste, die Informations- und Kommunikationstechnologien für Patienten, Verbraucher oder Angehörige der Gesundheitsberufe nutzen.&lt;span&gt;&lt;sup&gt;9, 10&lt;/sup&gt;&lt;/span&gt; In der Dermatologie sind bereits heute vielversprechende DHI im Einsatz,&lt;span&gt;&lt;sup&gt;11&lt;/sup&gt;&lt;/span&gt; darunter Anwendungen künstlicher Intelligenz bei der Diagnosestellung,&lt;span&gt;&lt;sup&gt;12&lt;/sup&gt;&lt;/span&gt; Teledermatologie für Überweisungen, Diagnosen oder die Überwachung von Hautkrankheiten&lt;span&gt;&lt;sup&gt;13-15&lt;/sup&gt;&lt;/span&gt; und patientenorientierte Anwendungen zur Verbesserung der Medikamenteneinnahme.&lt;span&gt;&lt;sup&gt;16&lt;/sup&gt;&lt;/span&gt; Die s2k-Leitlinie Teledermatologie aus dem Jahr 2020 unterstützt den Einsatz der Teledermatologie für bestimmte Indikationen, betont jedoch auch die Notwendigkeit von weiterer Evidenz zur Bewertung der damit verbundenen Vorteile und Risiken.&lt;span&gt;&lt;sup&gt;17&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Trotz der vorhandenen digitalen Gesundheitsinfrastrukturen hinkt die Digitalisierung im Gesundheitswesen in Deutschland hinter anderen westlichen Ländern hinterher.&lt;span&gt;&lt;sup&gt;18&lt;/sup&gt;&lt;/span&gt; In der Dermatologie haben selbst auf dem Höhepunkt der COVID-19-Pandemie nur wenige Dermatologen digitale Gesundheitsinfrastrukturen in ihre Behandlung integriert.&lt;span&gt;&lt;sup&gt;19, 20&lt;/sup&gt;&lt;/span&gt; Darüber hinaus ist die Nutzung durch Patienten mit Hauterkrankungen relativ gering, beispielsweise nutzten nur 10 % eine elektronische Patientenakte (ePA).&lt;span&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/span&gt; Die Komplexität des deutschen Gesundheitssystems trägt zu geringen DHI-Implementierungsraten bei, wobei Faktoren wie fehlende Interoperabilität, hohe Datenschutzstandards oder fehlende Anreize für Kliniken und ambulante Praxen eine Rolle spielen.&lt;span&gt;&lt;sup&gt;22&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Weitere Gründe für die geringe Nutzungsrate von DHI, die von Dermatologen beschrieben werden, können die geringe Akzeptanz von DHI bei Patienten und deren begrenzten digitalen Kompetenzen sein.&lt;span&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/span&gt; Einige Veröffentlichungen zeigen jedoch eine ausreichende bis hohe Akzeptanz von DHI und ausre","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":"24 9","pages":"1264-1276"},"PeriodicalIF":5.0,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ddg.70010x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148903660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}